Type 2 Diabetes as a Predictor of Fibrosis and Mortality in MAFLD: A Literature Review
College
College of Arts and Sciences
Mentor Information
Dr. Wojciech Blonski
Description
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a leading driver of progressive liver fibrosis and premature mortality. However, MAFLD is clinically heterogeneous, comprising three distinct metabolic sub-phenotypes: obesity- driven, diabetes-driven, and metabolically dysregulated. Whether specific sub-phenotypes confer differential risk of fibrosis progression and mortality remains unclear. To identify which MAFLD sub-phenotype is associated with the greatest risk of advanced liver fibrosis and all-cause mortality through review of existing literature. A systematic literature review was conducted using PubMed with search terms “liver fibrosis,” “metabolic dysfunction,” “cardiovascular,” “diabetes,” and “obesity,” yielding 151 papers screened. Articles not explicitly addressing MAFLD or published more than 10 years ago were excluded. Following application of inclusion criteria, 45 papers underwent full-text review and were included in final synthesis. Across multiple studies, type 2 diabetes was the strongest metabolic predictor of fibrosis progression, with diabetic patients showing the highest rates of fibrosis, hepatocellular carcinoma, and mortality. Obesity and insulin resistance further increased fibrotic burden. Cardiovascular disease was also a major contributor to mortality, particularly among patients with type 2 diabetes and obesity, highlighting the systemic nature of metabolic dysfunction. Patients with isolated hepatic steatosis generally had favorable long-term outcomes. The degree of liver fibrosis and type 2 diabetes were the primary determinants of prognosis. Diabetes is a key driver of adverse outcomes in MAFLD, with fibrosis acting as a predictor of mortality. Future research should prioritize non-invasive risk assessment tools for identification of high-risk metabolic sub-phenotypes to address current gaps in prevention and management of advanced liver
Type 2 Diabetes as a Predictor of Fibrosis and Mortality in MAFLD: A Literature Review
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a leading driver of progressive liver fibrosis and premature mortality. However, MAFLD is clinically heterogeneous, comprising three distinct metabolic sub-phenotypes: obesity- driven, diabetes-driven, and metabolically dysregulated. Whether specific sub-phenotypes confer differential risk of fibrosis progression and mortality remains unclear. To identify which MAFLD sub-phenotype is associated with the greatest risk of advanced liver fibrosis and all-cause mortality through review of existing literature. A systematic literature review was conducted using PubMed with search terms “liver fibrosis,” “metabolic dysfunction,” “cardiovascular,” “diabetes,” and “obesity,” yielding 151 papers screened. Articles not explicitly addressing MAFLD or published more than 10 years ago were excluded. Following application of inclusion criteria, 45 papers underwent full-text review and were included in final synthesis. Across multiple studies, type 2 diabetes was the strongest metabolic predictor of fibrosis progression, with diabetic patients showing the highest rates of fibrosis, hepatocellular carcinoma, and mortality. Obesity and insulin resistance further increased fibrotic burden. Cardiovascular disease was also a major contributor to mortality, particularly among patients with type 2 diabetes and obesity, highlighting the systemic nature of metabolic dysfunction. Patients with isolated hepatic steatosis generally had favorable long-term outcomes. The degree of liver fibrosis and type 2 diabetes were the primary determinants of prognosis. Diabetes is a key driver of adverse outcomes in MAFLD, with fibrosis acting as a predictor of mortality. Future research should prioritize non-invasive risk assessment tools for identification of high-risk metabolic sub-phenotypes to address current gaps in prevention and management of advanced liver
